|
Key
Features: |
|
| Title and year of the Document | Chinese Pharmacoeconomic Evaluation Guideline 2006 |
| Affiliation of authors | PE Center, Chinese Medical Doctor Association |
| Main policy objective | Providing recommendations for conduct of C/E studies in order to improve their quality, credibility and comparability
To support the decision-making process with sound C/E data |
| Standard reporting format included | Yes |
| Disclosure | Yes |
| Target audience of funding/ author’s interests | Who conduct PE evaluation or evaluate the PE studies(decision makers) |
| Perspective | Societal & health care sector |
| Indication | Approved indication |
| Target population | Be clearly specify |
| Subgroup analysis | Yes |
| Choice of comparator | Most prevalent treatment, most inexpensive treatment, no treatment |
| Time horizon | Should be clearly described and appropriate to the disease and treatment. Long-term effects should be emphasized |
| Assumptions required | Yes |
| Preferred analytical technique | CMA, CEA, CUA |
| Costs to be included | Depends on the aim of the study. All costs that are relevant must be distinguished and presented in detail. Report indirect costs separately. |
| Source of costs | Latest unit prices, give references. |
| Modeling | Yes, requires details |
| Systematic review of evidences | Yes, encourage meta-analysis |
| Preference for effectiveness over efficacy | Yes. RCTs, retrospective studies, intervention trials, patient databases, modeling all acceptable |
| Preferred outcome measure | Effectiveness by intention-to-treat principle, and expressed in natural units or QALY |
| Preferred method to derive utility | SG, TTO or VAS. Should justify the selection |
| Equity issues stated | Yes |
| Discounting costs | Yes, rates explained , Presented with and without discounting |
| Discounting outcomes | Yes, rates explained , Presented with and without discounting |
| Sensitivity analysis-parameters and range | All key uncertain parameters, within a defined area, or best/worst case scenario |
| Sensitivity analysis-methods | One-way, multi-way, may be probabilistic analysis
Details be given of the statistical tests performed |
| Presenting results | Most clear way, Reports both in disaggregated and aggregated form |
| Incremental analysis | Yes |
| Total C/E | Yes |
| Portability of results (Generalizability) | Yes, Studies must refer to the national context |
| Financial impact analysis | Yes |
| Mandatory or recommended or voluntary | Recommended |
